search
Back to results

Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior

Primary Purpose

Cardiovascular Diseases, Mood Disorders, Inflammation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fish Oil
Soybean Oil (Placebo)
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Cardiovascular Diseases focused on measuring Fish Oil, Omega-3 fatty acids, Affect, Depression, Anger, Nutrition, Impulsivity, Aggression, Cognition, Behavior

Eligibility Criteria

30 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Currently employed at least 25 hours a week, but does not regularly work the third shift (i.e., night shift)
  • English is primary language
  • Consumes less than 300 mg/day of long-chain omega-3 fatty acids.

Exclusion Criteria:

  • Serious allergy to fish (e.g., anaphylaxis, bronchospasm, serious skin reaction)
  • History of atherosclerotic disease (e.g., myocardial infarction) or treatment of angina or claudication (e.g., angioplasty)
  • Reported history of schizophrenia or bipolar disorder
  • Long-term hepatitis
  • Kidney failure
  • Stroke or other neurological disorder
  • Lung disease requiring drug treatment
  • Stage 2 high blood pressure, defined as systolic blood pressure of 160 mm Hg or greater and diastolic blood pressure of 100 mm Hg or greater
  • Alcohol consumption of more than five drinks per day each week (i.e., more than 35 alcoholic drinks each week)
  • Pregnant or breastfeeding
  • Currently taking any cardiovascular, psychotropic, glucocorticoid, lipid-lowering, insulin, or weight loss medications
  • Currently taking fish oil supplements

Sites / Locations

  • University of Pittsburgh

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Fish Oil

Placebo

Arm Description

Participants will take fish oil supplements daily for 4 months.

Participants will take soybean oil (placebo) supplements daily for 4 months.

Outcomes

Primary Outcome Measures

Circulating Serum Interleukin-6 (IL-6)
Systemic inflammation: fasting serum Interleukin-6 (IL-6)
C-reactive Protein (CRP)
fasting serum C-reactive protein (CRP) in milligrams per liter (mg/L)
Negative Affect
Negative affect questions adapted from the Positive and Negative Affect Schedule - Expanded Form administered via ecological momentary assessment. The minimum value is 1, and the maximum value is 6. A higher score are worse (more negative affect).
Impulsivity
Barratt Impulsiveness Scale. The minimum value is 34, and the maximum value is 120. A higher score suggests a worse outcome.
Aggression
Bus-Perry Aggression Questionnaire. The minimum value is 14, and the maximum value is 53. A higher score suggests a worse outcome.
Hostility, Barefoot Score
The 27-item Barefoot Hostility Scale. The minimum value is 1, and the maximum value is 30. A higher score suggests a worse outcome.
Trait Anger
State-Trait Anger Expression Inventory. The minimum value is 10, and the maximum value is 40. A higher score suggests a worse outcome.
Anger Expression
State-Trait Anger Expression Inventory. The minimum value is 0, and the maximum value is 72. A higher score suggests a worse outcome.
Type A, Total Score
Structured Interview - Type A Behavior Pattern using the Interpersonal Hostility Assessment Technique (IHAT). The minimum value is 0, and the maximum value is 12. A higher score suggests a worse outcome.
Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Paced Respiration
Mean successive difference in inter-beat intervals natural log transformed paced respiration in milliseconds
High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration
High frequency (.12 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz units (Hz)
Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration
Total power (0 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz (Hz) units.
Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Unpaced Respiration
Mean successive difference in inter-beat intervals natural log transformed unpaced respiration in milliseconds (msec)
High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration
High frequency (.12 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units
Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration
Total power (0 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units

Secondary Outcome Measures

Executive Function
Executive function was comprised of trail making B - A time, digit span forward and digit span backward completions. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Learning / Episodic Memory
Learning/episodic memory was comprised of d' from the four word memory task and the average performance across all trials of the Rey auditory verbal learning test. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Psychomotor Speed
Psychomotor speed was comprised of trail making A time, Stroop word-only time and color-only time. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Fluid Intelligence
This outcome was based upon matrix reasoning task raw score, block design task raw score and spatial span forward raw score. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Moderation of Effects of Fish Oil on Inflammatory Markers by Select Genetic Polymorphisms
Circulating serum concentrations of IL6 and CRP before and after supplementation with fish oil or placebo.

Full Information

First Posted
April 18, 2008
Last Updated
May 20, 2021
Sponsor
University of Pittsburgh
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00663871
Brief Title
Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior
Official Title
BioBehavioral Studies of Cardiovascular Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
June 2008 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Omega-3 fatty acids are a certain kind of fish fat that has recently been shown to have health benefits. This study will examine the effectiveness of fish oil supplementation for reducing the early signs of heart disease risk and for improving mood, impulsivity, and anger levels.
Detailed Description
Cardiovascular disease (CVD) is a broad term that includes diseases that affect the heart and blood vessels, including coronary heart disease, heart failure, high blood pressure, stroke and vascular dementia. CVD is the leading cause of death in the United States, resulting in 700,000 deaths each year. Preliminary research has shown that increased consumption of fish, specifically the omega-3 fatty acids found in fish oil, has beneficial effects in people with CVD. Fish oil may also have positive effects on the psychological health and well-being of people with psychiatric disorders. However, more research is needed to confirm the positive physical and psychological effects of fish oil in healthy adults. The purpose of this study is to explore potentail effects of fish oil supplementation on CVD mechanisms and risk markers, and on depressive symptoms, antagonistic disposition, and levels of impulsivity and aggression. This study will enroll healthy adults who habitually consume low quantities of long-chain omega-3 fatty acids. Participants will be randomly assigned to receive either fish oil supplements or placebo on a daily basis for 4 months. Study visits will occur at baseline and Months 2 and 4. At the baseline and Month 4 visits, participants will undergo the following measures as primary study aims: blood collection for inflammatory markers; heart rate and variability measurements; and interviews, psychological tests, and questionnaires to assess mood, disposition, impulsivity, and aggression. As secondary aims, we will test for any effects of fish oil on cognitive performance and, if a main effect on inflammatory markers is found, we will test for moderation by select genetic polymorphisms. As an exploratory aim, we will test for any effects of fish oil on structural or functional brain imaging. (This exploratory aim was mistakenly listed as a secondary aim at the time of trial registration.)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases, Mood Disorders, Inflammation
Keywords
Fish Oil, Omega-3 fatty acids, Affect, Depression, Anger, Nutrition, Impulsivity, Aggression, Cognition, Behavior

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
272 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fish Oil
Arm Type
Active Comparator
Arm Description
Participants will take fish oil supplements daily for 4 months.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will take soybean oil (placebo) supplements daily for 4 months.
Intervention Type
Dietary Supplement
Intervention Name(s)
Fish Oil
Other Intervention Name(s)
Omega-3 Life Formula (PharmaOmega)
Intervention Description
Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
Intervention Type
Dietary Supplement
Intervention Name(s)
Soybean Oil (Placebo)
Intervention Description
Participants will take 2 grams of soybean oil supplements on a daily basis.
Primary Outcome Measure Information:
Title
Circulating Serum Interleukin-6 (IL-6)
Description
Systemic inflammation: fasting serum Interleukin-6 (IL-6)
Time Frame
Baseline and Month 4
Title
C-reactive Protein (CRP)
Description
fasting serum C-reactive protein (CRP) in milligrams per liter (mg/L)
Time Frame
baseline and month 4
Title
Negative Affect
Description
Negative affect questions adapted from the Positive and Negative Affect Schedule - Expanded Form administered via ecological momentary assessment. The minimum value is 1, and the maximum value is 6. A higher score are worse (more negative affect).
Time Frame
baseline and month 4
Title
Impulsivity
Description
Barratt Impulsiveness Scale. The minimum value is 34, and the maximum value is 120. A higher score suggests a worse outcome.
Time Frame
baseline and month 4
Title
Aggression
Description
Bus-Perry Aggression Questionnaire. The minimum value is 14, and the maximum value is 53. A higher score suggests a worse outcome.
Time Frame
baseline and month 4
Title
Hostility, Barefoot Score
Description
The 27-item Barefoot Hostility Scale. The minimum value is 1, and the maximum value is 30. A higher score suggests a worse outcome.
Time Frame
baseline and month 4
Title
Trait Anger
Description
State-Trait Anger Expression Inventory. The minimum value is 10, and the maximum value is 40. A higher score suggests a worse outcome.
Time Frame
baseline and month 4
Title
Anger Expression
Description
State-Trait Anger Expression Inventory. The minimum value is 0, and the maximum value is 72. A higher score suggests a worse outcome.
Time Frame
baseline and month 4
Title
Type A, Total Score
Description
Structured Interview - Type A Behavior Pattern using the Interpersonal Hostility Assessment Technique (IHAT). The minimum value is 0, and the maximum value is 12. A higher score suggests a worse outcome.
Time Frame
baseline and month 4
Title
Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Paced Respiration
Description
Mean successive difference in inter-beat intervals natural log transformed paced respiration in milliseconds
Time Frame
baseline and month 4
Title
High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration
Description
High frequency (.12 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz units (Hz)
Time Frame
baseline and month 4
Title
Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Paced Respiration
Description
Total power (0 to .40 Hz) heart rate variability natural log transformed paced respiration in Hertz (Hz) units.
Time Frame
baseline and month 4
Title
Mean Successive Difference in Inter-beat Intervals Natural Log Transformed Unpaced Respiration
Description
Mean successive difference in inter-beat intervals natural log transformed unpaced respiration in milliseconds (msec)
Time Frame
baseline and month 4
Title
High Frequency (.12 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration
Description
High frequency (.12 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units
Time Frame
baseline and month 4
Title
Total Power (0 to .40 Hz) Heart Rate Variability Natural Log Transformed Unpaced Respiration
Description
Total power (0 to .40 Hz) heart rate variability natural log transformed unpaced respiration in Hertz (Hz) units
Time Frame
baseline and month 4
Secondary Outcome Measure Information:
Title
Executive Function
Description
Executive function was comprised of trail making B - A time, digit span forward and digit span backward completions. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Time Frame
Baseline and Month 4
Title
Learning / Episodic Memory
Description
Learning/episodic memory was comprised of d' from the four word memory task and the average performance across all trials of the Rey auditory verbal learning test. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Time Frame
Baseline and Month 4
Title
Psychomotor Speed
Description
Psychomotor speed was comprised of trail making A time, Stroop word-only time and color-only time. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Time Frame
Baseline and Month 4
Title
Fluid Intelligence
Description
This outcome was based upon matrix reasoning task raw score, block design task raw score and spatial span forward raw score. Performance scores on each task were converted into Z-scores, and then averaged across tasks. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate higher function (better outcome). The analysis compared changes in Z-scores between the two treatment groups.
Time Frame
Baseline and Month 4
Title
Moderation of Effects of Fish Oil on Inflammatory Markers by Select Genetic Polymorphisms
Description
Circulating serum concentrations of IL6 and CRP before and after supplementation with fish oil or placebo.
Time Frame
Measured at Month 4
Other Pre-specified Outcome Measures:
Title
Structural & Functional MRI
Description
Measures of brain structure and function from magnetic resonance imaging
Time Frame
Baseline and month 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Currently employed at least 25 hours a week, but does not regularly work the third shift (i.e., night shift) English is primary language Consumes less than 300 mg/day of long-chain omega-3 fatty acids. Exclusion Criteria: Serious allergy to fish (e.g., anaphylaxis, bronchospasm, serious skin reaction) History of atherosclerotic disease (e.g., myocardial infarction) or treatment of angina or claudication (e.g., angioplasty) Reported history of schizophrenia or bipolar disorder Long-term hepatitis Kidney failure Stroke or other neurological disorder Lung disease requiring drug treatment Stage 2 high blood pressure, defined as systolic blood pressure of 160 mm Hg or greater and diastolic blood pressure of 100 mm Hg or greater Alcohol consumption of more than five drinks per day each week (i.e., more than 35 alcoholic drinks each week) Pregnant or breastfeeding Currently taking any cardiovascular, psychotropic, glucocorticoid, lipid-lowering, insulin, or weight loss medications Currently taking fish oil supplements
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew F. Muldoon, MD, MPH
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15260
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25373092
Citation
Muldoon MF, Ryan CM, Yao JK, Conklin SM, Manuck SB. Long-chain omega-3 fatty acids and optimization of cognitive performance. Mil Med. 2014 Nov;179(11 Suppl):95-105. doi: 10.7205/MILMED-D-14-00168.
Results Reference
background
PubMed Identifier
31581959
Citation
Leckie RL, Lehman DE, Gianaros PJ, Erickson KI, Sereika SM, Kuan DCH, Manuck SB, Ryan CM, Yao JK, Muldoon MF. The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial. Psychol Med. 2020 Oct;50(14):2425-2434. doi: 10.1017/S0033291719002617. Epub 2019 Oct 4.
Results Reference
result
PubMed Identifier
26497831
Citation
Muldoon MF, Laderian B, Kuan DC, Sereika SM, Marsland AL, Manuck SB. Fish oil supplementation does not lower C-reactive protein or interleukin-6 levels in healthy adults. J Intern Med. 2016 Jan;279(1):98-109. doi: 10.1111/joim.12442. Epub 2015 Oct 26.
Results Reference
result
PubMed Identifier
28121722
Citation
Ginty AT, Muldoon MF, Kuan DCH, Schirda B, Kamarck TW, Jennings JR, Manuck SB, Gianaros PJ. Omega-3 Supplementation and the Neural Correlates of Negative Affect and Impulsivity: A Double-Blind, Randomized, Placebo-Controlled Trial in Midlife Adults. Psychosom Med. 2017 Jun;79(5):549-556. doi: 10.1097/PSY.0000000000000453.
Results Reference
result
PubMed Identifier
24736647
Citation
Cipollina C, Salvatore SR, Muldoon MF, Freeman BA, Schopfer FJ. Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives. PLoS One. 2014 Apr 15;9(4):e94836. doi: 10.1371/journal.pone.0094836. eCollection 2014.
Results Reference
result
PubMed Identifier
20181791
Citation
Muldoon MF, Ryan CM, Sheu L, Yao JK, Conklin SM, Manuck SB. Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood. J Nutr. 2010 Apr;140(4):848-53. doi: 10.3945/jn.109.119578. Epub 2010 Feb 24.
Results Reference
result
PubMed Identifier
21753804
Citation
Liu JC, Conklin SM, Manuck SB, Yao JK, Muldoon MF. Long-chain omega-3 fatty acids and blood pressure. Am J Hypertens. 2011 Oct;24(10):1121-6. doi: 10.1038/ajh.2011.120. Epub 2011 Jul 14.
Results Reference
result
PubMed Identifier
17383013
Citation
Conklin SM, Harris JI, Manuck SB, Yao JK, Hibbeln JR, Muldoon MF. Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res. 2007 Jul 30;152(1):1-10. doi: 10.1016/j.psychres.2006.10.006. Epub 2007 Mar 23.
Results Reference
result
PubMed Identifier
17574755
Citation
Conklin SM, Gianaros PJ, Brown SM, Yao JK, Hariri AR, Manuck SB, Muldoon MF. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci Lett. 2007 Jun 29;421(3):209-12. doi: 10.1016/j.neulet.2007.04.086. Epub 2007 Jun 2.
Results Reference
result
PubMed Identifier
17991818
Citation
Conklin SM, Manuck SB, Yao JK, Flory JD, Hibbeln JR, Muldoon MF. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med. 2007 Dec;69(9):932-4. doi: 10.1097/PSY.0b013e31815aaa42. Epub 2007 Nov 8.
Results Reference
result
PubMed Identifier
20060277
Citation
Conklin SM, Runyan CA, Leonard S, Reddy RD, Muldoon MF, Yao JK. Age-related changes of n-3 and n-6 polyunsaturated fatty acids in the anterior cingulate cortex of individuals with major depressive disorder. Prostaglandins Leukot Essent Fatty Acids. 2010 Feb-Mar;82(2-3):111-9. doi: 10.1016/j.plefa.2009.12.002. Epub 2010 Jan 8.
Results Reference
result
PubMed Identifier
23884386
Citation
Muldoon MF, Erickson KI, Goodpaster BH, Jakicic JM, Conklin SM, Sekikawa A, Yao JK, Manuck SB. Concurrent physical activity modifies the association between n3 long-chain fatty acids and cardiometabolic risk in midlife adults. J Nutr. 2013 Sep;143(9):1414-20. doi: 10.3945/jn.113.174078. Epub 2013 Jul 24.
Results Reference
result

Learn more about this trial

Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior

We'll reach out to this number within 24 hrs